论文部分内容阅读
为了观察吲达帕胺降低血压的同时，是否对肾脏有保护作用，本文对26例高血压病患者于服用吲达帕胺前及服用8周后，分别采血及收集尿标本测定Ser、BUN、Ucr、UAlb、Uα1M、UNAG，并与30例正常人对照．结果发现，高血压病患者服药前UAlb、Uα1M、UANG较对照组明显升高；服药后在血压下降的同时UAlb、Uα1M较用药前显著降低，而Scr、BUN变化不大．作者还观察了该药的不良反应．探讨了作用原理，并认为应用吲达帕胺降压后UAlb、Uα1M降低，受损的肾功能得到了改善，提示该药对肾脏具有保护作用。
In order to observe whether indapamide reduces blood pressure and protects the kidney, 26 patients with hypertension before taking indapamide and 8 weeks after taking blood and urine samples were collected for determination of Ser, BUN, Ucr, UAlb, Uα1M, UNAG, and with 30 normal controls. The results showed that UAlb, Uα1M, UANG in hypertensive patients before treatment were significantly higher than those in the control group. UAb and Uα1M were decreased significantly while the blood pressure was decreased, while Scr and BUN did not change much. The authors also observed the drug’s adverse reactions. The principle of action was discussed. It was suggested that UAb and Uα1M decreased after indapamide administration and impaired renal function was improved, suggesting that the drug has a protective effect on the kidneys.